Pfizer/Aventis Exubera NDA Delayed Until 2002; FDA May Require More Data

Pfizer/Aventis' Exubera inhaled insulin NDA is not expected to be filed until the second half of 2002 if FDA requires additional data, according to development partner Inhale Therapeutic Systems.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet